358 related articles for article (PubMed ID: 17234366)
1. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.
Pérez de los Cobos J; Siñol N; Trujols J; del Río E; Bañuls E; Luquero E; Menoyo A; Queraltó JM; Baiget M; Alvarez E
Drug Alcohol Depend; 2007 Jul; 89(2-3):190-4. PubMed ID: 17234366
[TBL] [Abstract][Full Text] [Related]
2. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
3. A satisfaction survey of opioid-dependent clients at methadone treatment centres in Spain.
Pérez de los Cobos J; Fidel G; Escuder G; Haro G; Sánchez N; Pascual C; Valderrama JC; Valero S; Trujols J
Drug Alcohol Depend; 2004 Mar; 73(3):307-13. PubMed ID: 15036553
[TBL] [Abstract][Full Text] [Related]
4. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2D6 genotype and methadone steady-state concentrations.
Eap CB; Broly F; Mino A; Hämmig R; Déglon JJ; Uehlinger C; Meili D; Chevalley AF; Bertschy G; Zullino D; Kosel M; Preisig M; Baumann P
J Clin Psychopharmacol; 2001 Apr; 21(2):229-34. PubMed ID: 11270921
[TBL] [Abstract][Full Text] [Related]
6. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.
Diefenbach K; Jaeger K; Wollny A; Penzel T; Fietze I; Roots I
Sleep Med; 2008 Jul; 9(5):579-82. PubMed ID: 17921051
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
8. Patient perspectives on methadone maintenance treatment in the Valencia Region: dose adjustment, participation in dosage regulation, and satisfaction with treatment.
Pérez de Los Cobos J; Trujols J; Valderrama JC; Valero S; Puig T
Drug Alcohol Depend; 2005 Sep; 79(3):405-12. PubMed ID: 15869846
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity?
Wong SH; Wagner MA; Jentzen JM; Schur C; Bjerke J; Gock SB; Chang CC
J Forensic Sci; 2003 Nov; 48(6):1406-15. PubMed ID: 14640293
[TBL] [Abstract][Full Text] [Related]
11. Patient satisfaction with methadone maintenance treatment: the relevance of participation in treatment and social functioning.
Trujols J; Garijo I; Siñol N; del Pozo J; Portella MJ; Pérez de los Cobos J
Drug Alcohol Depend; 2012 Jun; 123(1-3):41-7. PubMed ID: 22071121
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T
Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
[TBL] [Abstract][Full Text] [Related]
13. Analysis of CYP2D6 genotype and response to tetrabenazine.
Mehanna R; Hunter C; Davidson A; Jimenez-Shahed J; Jankovic J
Mov Disord; 2013 Feb; 28(2):210-5. PubMed ID: 23280482
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
[TBL] [Abstract][Full Text] [Related]
15. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
19. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
[TBL] [Abstract][Full Text] [Related]
20. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?
Laika B; Leucht S; Heres S; Steimer W
Pharmacogenomics J; 2009 Dec; 9(6):395-403. PubMed ID: 19451914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
